Venture(US:VEMLY) Sou Hu Cai Jing·2025-08-20 02:34Group 1 - The pharmaceutical and biotechnology sector has increased by 25.02% year-to-date, ranking 4th among 31 industries in the Shenwan index, with a current PE valuation of 31.31 times, which is at the historical median level [1] - The National Healthcare Security Administration has recently issued the "Interim Measures for Disease-Specific Payment Management," promoting payment reform and clarifying total budget management and grouping adjustment cycles [1] - The preliminary list of innovative drugs for medical insurance and commercial insurance for 2025 has been released, with several cancer drugs (such as bispecific antibodies, CAR-T therapies, and ADCs) and new chronic disease drugs passing the review, expected to see rapid growth once included in the dual directory [1] Group 2 - The medical device sector is experiencing continuous policy support, with a recommendation to focus on innovative directions such as brain-computer interfaces [1] - The China Innovation Biopharmaceutical Index (399275), tracked by the Guotai medical ETF (159377), can have a daily fluctuation of up to 20%, focusing on innovative biopharmaceutical companies involved in biotechnology, genetic engineering, and new vaccine and drug development [1] - The release of industry policy dividends indicates growth potential in sub-sectors such as innovative drugs and medical devices [1]